Pilot clinical trial of 18F-fluorodeoxyglucose positron-emission mammography in the surgical management of breast cancer.


Journal Article

BACKGROUND: High-resolution positron-emission mammography (PEM) is a new device, which allows the imaging of breast tissue. A prospective study was performed to assess the accuracy of PEM in newly diagnosed breast cancer patients. METHODS: In a prospective multicenter study, 44 women with confirmed breast cancers were imaged with a high-resolution PEM scanner (Naviscan PET Systems, Rockville, MD) with 18F-fluorodeoxyglucose. The images were blindly evaluated and were compared with final pathology. RESULTS: The majority of the index lesions were seen on PEM (89%, 39/44). PEM detected 4 of 5 incidental breast cancers, 3 of which were not seen by any other imaging modalities. Of 19 patients undergoing breast-conserving surgery, PEM correctly predicted 6 of 8 (75%) patients with positive margins and 100% (11/11) with negative margins. CONCLUSION: The current PEM device shows promise in detecting breast malignancies and may assist in the planning of adequate partial mastectomy procedures to better ensure negative margins.

Full Text

Cited Authors

  • Tafra, L; Cheng, Z; Uddo, J; Lobrano, MB; Stein, W; Berg, WA; Levine, E; Weinberg, IN; Narayanan, D; Ross, E; Beylin, D; Yarnall, S; Keen, R; Sawyer, K; Van Geffen, J; Freimanis, RL; Staab, E; Adler, LP; Lovelace, J; Shen, P; Stewart, J; Dolinsky, S

Published Date

  • October 2005

Published In

Volume / Issue

  • 190 / 4

Start / End Page

  • 628 - 632

PubMed ID

  • 16164937

Pubmed Central ID

  • 16164937

International Standard Serial Number (ISSN)

  • 0002-9610

Digital Object Identifier (DOI)

  • 10.1016/j.amjsurg.2005.06.029


  • eng

Conference Location

  • United States